Technology area: Chemistry & Materials
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Medicarbone Inc. has 1 pending office action in the Chemistry & Materials technology area. This action is assigned to 1 distinct art unit, reflecting a singular technical focus for the company's current prosecution. The matter is under the review of 1 distinct examiner, PEPITONE, MICHAEL F. This concentration of the pending workload into a single art unit and examiner suggests a very specific regulatory path for the company's innovations at this time.
PEPITONE, MICHAEL F is the busiest examiner for the portfolio, managing 1 pending office action. This examiner is the only one currently reviewing a pending action for the company. The outcome of the current prosecution cycle is therefore concentrated on the interactions with this specific examiner. There is no current opportunity to compare examiner behavior across different applications within this portfolio, as only 1 pending office action exists.
The presence of 1 pending office action in 1 distinct art unit means there is no diversification in the technical review process at this time. Practitioners must address the specific requirements of PEPITONE, MICHAEL F within that single art unit. With only 1 pending office action, the company's current prosecution activity is highly focused. This concentrated environment requires a dedicated approach to the single application currently under review in the 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PEPITONE, MICHAEL F | 1 | 74.4% | +22.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18770157 | METHOD OF CREATING BIOCOMPATIBLE POLYMERIC RESIN SYSTEMS FOR BONE REPAIR AND MANAGEMENT | PEPITONE, MICHAEL F | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18770157 | METHOD OF CREATING BIOCOMPATIBLE POLYMERIC RESIN SYSTEMS FOR BONE REPAIR AND MANAGEMENT | PEPITONE, MICHAEL F | — |
| Art Unit | Apps |
|---|---|
| 1767 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18770157 | METHOD OF CREATING BIOCOMPATIBLE POLYMERIC RESIN SYSTEMS FOR BONE REPAIR AND MANAGEMENT | PEPITONE, MICHAEL F | 1767 | §103§112Other | Non-Final OA | — | Pending | Jul 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedicarbone Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael F Pepitone has the most, with 1 of Medicarbone Inc.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
